The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.

Company Guidance

In the Q3 2025 conference call, Cipher Pharmaceuticals reported robust financial metrics, highlighting meaningful growth attributed to the U.S.-based Natroba business. Natroba and its authorized generic Spinosad generated $8.1 million in sales, marking a 4% sequential increase from the previous quarter. This growth was attributed to product seasonality and strong profitability, with a gross profit of $7 million and a gross margin of 86%. The Natroba business contributed $5 million to the adjusted EBITDA, which totaled $7.3 million for the company during the quarter. Cipher also reported a significant reduction in its revolving credit facility from $40 million to an $8 million balance, reflecting their focus on deleveraging. The company's broader strategy includes launching a direct-to-consumer sales model in early 2023 to expand the Natroba business, pursuing complementary products for commercialization, launching Natroba in Canada, and exploring global out-licensing opportunities. Overall, Cipher Pharmaceuticals is focusing on growth and shareholder value while maintaining a strong financial position with $8.4 million in cash and $13 million in outstanding debt by the quarter's end.

Strong Performance of Natroba Business

Sales from Natroba and its authorized generic Spinosad reached $8.1 million in Q3 2025, a 4% sequential increase. The gross margin was 86%, with strong profitability reflected in an adjusted EBITDA of $5 million.

Significant Debt Repayment

The company repaid $17 million on its revolving credit facility, reducing the balance to $8 million from an initial $40 million. This demonstrates strong cash flow and financial management.

Revenue Growth

Net revenue for Q3 2025 increased by 24% year-over-year, and for the 9-month period, it rose by 78% compared to the same period in 2024, driven by the addition of the U.S.-based Natroba business.

Strong Adjusted EBITDA Growth

Adjusted EBITDA increased by 79% for Q3 2025 and 97% for the 9-month period, compared to the same periods in 2024.

Net Income Growth

Net income for Q3 2025 was $5.5 million, a significant rise from $0.3 million in the same quarter of the previous year. For the 9-month period, net income was $14 million, up from $8.2 million year-over-year.

Cipher Pharmaceuticals (DE:PHE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:PHE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	0.13 / -	0.113	―	―	―
Nov 06, 2025	2025 (Q3)	0.18 / 0.18	0.009	2000.00% (+0.17)	―
Aug 07, 2025	2025 (Q2)	0.14 / 0.19	0.104	83.33% (+0.09)	―
May 08, 2025	2025 (Q1)	0.09 / 0.09	0.173	-50.00% (-0.09)
Mar 18, 2025	2024 (Q4)	0.16 / 0.11	0.26	-56.67% (-0.15)	―
Nov 07, 2024	2024 (Q3)	0.12 / <0.01	0.234	-96.30% (-0.23)	―
Aug 08, 2024	2024 (Q2)	0.10 / 0.10	0.104	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	0.09 / 0.17	0.087	100.00% (+0.09)	―
Mar 14, 2024	2023 (Q4)	0.08 / 0.26	0.675	-61.54% (-0.42)	―
Nov 09, 2023	2023 (Q3)	0.06 / 0.23	0.087	170.00% (+0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:PHE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	€9.00	€8.20	-8.89%
Aug 07, 2025	€8.35	€8.55	+2.40%
May 08, 2025	€9.25	€8.85	-4.32%
Mar 18, 2025	€7.55	€7.50	-0.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cipher Pharmaceuticals (DE:PHE) report earnings?

Cipher Pharmaceuticals (DE:PHE) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).

What is Cipher Pharmaceuticals (DE:PHE) earnings time?

Cipher Pharmaceuticals (DE:PHE) earnings time is at Mar 12, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Cipher Pharmaceuticals stock?

The P/E ratio of Cipher Pharmaceuticals is N/A.

What is DE:PHE EPS forecast?

DE:PHE EPS forecast for the fiscal quarter 2025 (Q4) is 0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing